154 search results for: type 2 inflammation

CEORL-HNS <b>2</b>0<b>2</b>6 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP
Rhinology
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP
expert video

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

View more
World Anosmia Day <b>2</b>0<b>2</b>6
On Demand
World Anosmia Day 2026

Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

World Anosmia Awareness Day
On Demand
World Anosmia Awareness Day

Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.

Why Is It Important to Assess Lung Function in Pediatric Asthma?
Pulmonology
Why Is It Important to Assess Lung Function in Pediatric Asthma?
interactivity

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.

View more
Complex EoE Pathophysiology Beyond Esophageal Eosinophilia
Gastroenterology
Complex EoE Pathophysiology Beyond Esophageal Eosinophilia
expert video

Dr. Jonathan Spergel and Prof. Arjan Bredenoord highlight the importance of different immune cells in type 2 inflammation in EoE.

View more
What Went Wrong? How Dysregulated <b>Type</b> <b>2</b> Immunity Contributes to AD, PN, CSU, and BP
Dermatology
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
slide presentation

This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

View more
What Went Wrong? How Dysregulated <b>Type</b> <b>2</b> Immunity Contributes to AD, PN, CSU, and BP
Dermatology
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
expert video

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

View more
Atopic Dermatitis at an Inflection Point: Refining Outcomes Through Timely, Targeted Intervention
Dermatology
Atopic Dermatitis at an Inflection Point: Refining Outcomes Through Timely, Targeted Intervention
expert video

At the 2026 EADV Congress, Prof. Tilo Biedermann and Drs. Nicole Chase and Lisa Swanson present a holistic view of atopic dermatitis (AD) management from childhood to adulthood centered around type 2 inflammation. Beginning with the hypothesis that reduced exposure to helminths in increasingly industrialized societies may have diminished natural immunomodulatory mechanisms, they explore how dysregulated type 2 inflammation can manifest as AD and extend beyond the skin. The discussion then focuses on adults with uncontrolled AD, highlighting the multidimensional, cumulative burden of disease across the lifespan—and how targeted systemic therapy may help achieve sustained disease control. Finally, the faculty explore pediatric AD as a critical window for early intervention, with the potential to alter disease progression and prevent comorbidities.

View more
Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
Dermatology
Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
expert video

Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.

View more
ERS <b>2</b>0<b>2</b>6 | Breaking Silos Between Asthma and CRSwNP: Loss of Smell as a Marker of Unified Airway Disease
Pulmonology
ERS 2026 | Breaking Silos Between Asthma and CRSwNP: Loss of Smell as a Marker of Unified Airway Disease
expert video

Join experts Roland Buhl, Joaquim Mullol, and Giselle Mosnaim as they discuss the role of type 2 inflammation across the unified airway, with a focus on the amplified burden and the difficulty controlling inflammation when asthma and CRSwNP coexist.

View more
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Dermatology
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Podcast

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

View more